Last update 21 Nov 2024

Calcium Hopantenate

Last update 21 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Calcium hopantenate hydrate (JAN), D-Homopantothenic acid, Hopantenic Acid

+ [4]

Target-

Mechanism-

Therapeutic Areas

Nervous System Diseases

Active Indication

Nervous System Diseases

Inactive Indication-

Originator Organization-

Active Organization-

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Structure

Molecular FormulaC10H19NO5

InChIKeySBBDHANTMHIRGW-QMMMGPOBSA-N

CAS Registry18679-90-8

View All Structures (2)

100 Clinical Results associated with Calcium Hopantenate

100 Translational Medicine associated with Calcium Hopantenate

100 Patents (Medical) associated with Calcium Hopantenate

140

Literatures (Medical) associated with Calcium Hopantenate

01 Jan 2024·S.S. Korsakov Journal of Neurology and Psychiatry

Clinical and neurophysiological manifestations of sluggish cognitive tempo in children

Article

Author: Cherednichenko, D V ; Anisimova, T I ; Didur, M D ; Chutko, L S ; Yakovenko, E A ; Surushkina, S Yu ; Chekalova, S A

OBJECTIVETo study the clinical and neurophysiological features of children with low cognitive tempo (NCT), as well as the effectiveness of the drug Pantogam in the treatment of this pathology.MATERIAL AND METHODSA total of 90 children aged 8 to 10 years were examined. Of these, the main study group consisted of 30 children with NCT, the comparison group consisted of 30 children with a combined type of attention deficit hyperactivity disorder ADHD (ADHD-K), the control group consisted of 30 children without neuropsychiatric disorders. The study used clinical, neurophysiological (electroencephalography (EEG)) and parametric methods. The CMAS scale of apparent anxiety (The Children's Form of Manifest Anxiety Scale), the SNAP-IY scale (assessment of the degree of inattention, hyperactivity and impulsivity), the TOVA computer test (the Test of Variables of Attention), the scale «SCT» (Sluggish Cognitive Tempo) for assessing manifestations of low cognitive tempo, the «RAM» technique for quantifying working memory. Pantogam was used to treat patients at a dose of 750 mg per day for 8 weeks.RESULTSPatients with NCT are characterized by more pronounced attention disorders compared with healthy peers and with children with ADHD-K, and they have a decrease in mainly not selective attention, but the overall level of functional activity. Also, the group of children with NCT has an increased level of anxiety compared to the group of children with ADHD. A comparative analysis of the level of impulsivity showed that children with NCT are less characterized by a deficit in inhibition processes. According to the quantitative analysis of the EEG, specific changes in functional activity in the frontal and central regions of the cerebral cortex were revealed (a statistically significant increase in the ratio of absolute theta rhythm to beta1 rhythm, compared with other groups), reflecting insufficient cortical arousal and less focused neural states. When re-evaluating the condition of children with NCT after a course of therapy with Pantogam, an improvement in the form of a decrease in the degree of inattention, the severity of memory impairment and a decrease in reaction time was recorded in 60% of cases. According to quantitative EEG analysis, there was a significant decrease in the ratio of absolute theta rhythm to beta1 rhythm in the central leads of both hemispheres and in the parietal-temporal leads of the left hemisphere, indicating an increase in the level of overall activation of the cerebral cortex after a course of treatment.CONCLUSIONClinical and neurophysiological differences were revealed in patients with NCT and with combined ADHD. It has been shown that the use of Pantogam for the treatment of children with NCT leads not only to a decrease in the main manifestations of this disorder, but also to an improvement in the functional state of the brain.

01 Jan 2023·Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova

Clinical and psychological manifestations of emotional burnout in mothers of children with neuropsychiatric diseases (on a model of ADHD)

Article

Author: Anisimova, T I ; Sergeev, A V ; Cherednichenko, D V ; Surushkina, S Yu ; Chutko, L S ; Yakovenko, E A ; Didur, M D ; Timosheva, Y A ; Chekalova, S A ; Madjidova, E N

OBJECTIVETo evaluate the therapeutic efficacy of Pantogam aktiv in the treatment of clinical manifestations of burnout in mothers of children with ADHD.MATERIAL AND METHODSUnder observation were 108 mothers of children with attention deficit hyperactivity disorder (ADHD) aged 25 to 50 years, who had symptoms of burnout in the clinical picture during the initial visit. The following research methods were used in the work: clinical history taking, neurological examination, S. Maslach questionnaire for assessing the burnout manifestations, subjective asthenia rating scale (MFI-20) with five subscales, digital fatigue rating scale (10-point variant), quantitative assessment of autonomic changes (questionnaire A.M. Wein), Spielberger-Khanin Scale for assessing emotional disorders, psychophysiological study of cognitive functions: test of attention variables TOVA (the Test of Variables of Attention). For the treatment of patients, the drug Pantogam Active was used in capsules of 300 mg, at a daily dose of 900 mg (2 capsules in the morning and 1 capsule in the afternoon) for 8 weeks.RESULTSA re-examination after a course of treatment showed improvement in 68.5% of patients. After treatment, there was a significant decrease in the severity of such indicators of burnout as emotional exhaustion and depersonalization, a significant decrease in the average values according to the A.M. Wayne, a decrease in reactive anxiety, a statistically significant improvement in attention and a decrease in impulsivity (p<0.05).CONCLUSIONThus, the results of the study indicate that the use of Pantogam active in the treatment of clinical manifestations of parental burnout is characterized by high efficiency. After treatment, there is a significant decrease in fatigue, asthenia, anxiety, and total indicators characterizing burnout. The data obtained make it possible to recommend the use of Pantogam aktiv in the treatment of clinical manifestations of parents burnout in children with neurological diseases.

01 Jan 2022·Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova

Modern application possibilities hopanthenic acid (Pantocalcin) in treatmentdiseases of the nervous system in children

Article

Author: Nemkova, S A

The review analyzes the current possibilities of using hopanthenic acid (Pantocalcin) in the treatment of diseases of the nervous system in children (perinatal CNS lesions, developmental delays, cerebral palsy, ADHD, tics, enuresis, cognitive and neurotic disorders), taking into account modern standards and clinical recommendations. The results of numerous studies demonstrate that Pantocalcin is a highly effective and safe drug in the treatment of diseases of the nervous system in children with complex neurometabolic, neuroprotective, neurotrophic properties.

100 Deals associated with Calcium Hopantenate

External Link

KEGG	Wiki	ATC	Drug Bank
D03255	Calcium Hopantenate	N	DB14044

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Nervous System Diseases	-	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis